Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study
Felipe Furtado(Harvard University), Onofrio A. Catalano(Harvard University), Motaz Qadan(Massachusetts General Hospital), Robin Striar(Harvard University), Márk Vangel(Massachusetts General Hospital), Lina García Cañamaque(Hospital Universitario HM Sanchinarro), David Groshar(Tel Aviv University), Theodore S. Hong(Massachusetts General Hospital), Lale Umutlu(Essen University Hospital), Susanna I. Lee(Health Advances (United States)), Cristina R. Ferrone(Cedars-Sinai Medical Center), David P. Ryan(East Carolina University), David A. Rosman(Harvard University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Carlos Fernández‐del Castillo(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Colin D. Weekes(Massachusetts General Hospital)
Cited by 24
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k